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ABSTRACT 
 
Objective: The putative protein tyrosine kinase (PTK) inhibitor tyrphostin AG126 has proven 
beneficial in various models of inflammatory diseases. Yet molecular targets and cellular 
mechanisms remained enigmatic. 
Methods: Effects of AG126 were investigated in mice with experimental autoimmune 
encephalomyelitis (EAE), a model for multiple sclerosis, based on clinical scoring, histology 
and analysis of inflammatory infiltrates. Cellular mechanisms were determined by assays for 
antigen presentation, T cell and microglia activation, also involving mouse strains transgenic 
for a myelin-specific T cell receptor or with deficiencies in Toll-like receptor (TLR) signaling 
proteins. Molecular mechanisms and targets of AG126 were identified by a combination of 
spectroscopic, bio/chemical and cell-based studies.  
Results: In EAE, AG126 ameliorates the clinical symptoms, diminishes encephalitogenic 
Th17 differentiation, reduces inflammatory CNS infiltration as well as microglia activation 
and attenuates myelin damage. It impedes with T(h17) cell activation and directly inhibits 
Bruton’s tyrosine kinase (BTK), a PTK associating with B cell receptor and TLR signaling. 
However, BTK inhibition cannot account for the entire activity spectrum. Effects on TLR-
induced proinflammatory cytokines in microglia involve AG126 hydrolysis and conversion of 
its dinitrile side chain to malononitrile (MN). Notably, while liberated MN can subsequently 
mediate critical AG126 features, full protection in EAE still requires delivery of the intact 
AG126.  
Interpretation: The anti-inflammatory potential of AG126 and especially its interference 
with TLR signaling rely on a dual mechanism encompassing BTK and a novel MN-sensitive 
target. Both principles bear great potential for the therapeutic management of disturbed innate 
and adaptive immune functions. 
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INTRODUCTION 
 
Excessive inflammation can precipitate tissue impairment, up to organ failure with lethal 
outcome. The CNS is especially vulnerable to dysregulated inflammatory processes often 
associating with infection, trauma, stroke, neurodegenerative or autoimmune diseases, such as 
multiple sclerosis (MS), the most common CNS autoimmune disease 1,2. Strategies have been 
developed to moderate uncontrolled immune responses 2-5. Yet some cause serious side 
effects. In MS, for instance, recently developed treatments aim at specific elements of 
pathogenesis more effectively and conveniently, but run a risk of opportunistic infections or 
secondary autoimmunity 6-10. A search for alternative anti-inflammatory compounds should 
thus also consider novel targets. 
 Tyrphostins comprise a class of synthetic protein tyrosine kinase (PTK) inhibitors that 
were originally developed for cancer treatment 11. As tyrosine analogues they are designed to 
interfere with tyrosine phosphorylation in PTK substrates. Tyrphostins could thereby offer 
more selectivity than PTK inhibitors aiming at the common ATP binding site. In terms of 
potency, tyrphostins would compete with the rare protein substrates rather than the abundant 
ATP. Since PTKs are involved in virtually all cellular functions as positive and negative 
regulators of signaling 5, tyrphostins also proved beneficial in inflammatory conditions 12,13. 
 Tyrphostin AG126 (α-cyano-[3-hydroxy-4-nitro]cinnamonitrile) was found to rescue 
mice from lethal consequences of bacterial lipopolysaccharide (LPS) administration in a 
model of septic shock 14. Subsequent studies confirmed protective actions in various 
inflammatory disease models 15-25. We contributed findings regarding CNS complications, 
showing AG126 interference with microglial reactions to Toll-like receptor (TLR) activation 
26-29. Expressed by innate immune cells, such as CNS microglia, TLRs trigger crucial 
responses to infection and tissue damage, including production of proinflammatory cytokines 
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30,31. However, despite its obvious anti-inflammatory potential, the affected PTK activity and 
the cellular mechanisms of AG126 remained unknown.  
 Here, we identify Bruton’s tyrosine kinase (BTK) as a target of AG126, a Tec family 
member known for key roles in B cell receptor (BCR) signaling and adaptive immunity 32. 
BTK deficiency causes X-linked agammaglobulinemia, the most common human 
monogenetic immunodeficiency with extreme susceptibility to infection 32. On the other hand, 
BTK inhibition promises clinical success in treatments of lymphoma 33,34. Since BTK also 
associates with TLRs 35,36, further roles emerge for innate immune cells 37. X-linked 
immunodeficient (Xid) mice lacking functional BTK present with reduced severity of 
inflammatory diseases 37. 
 We show that AG126 protects mice with experimental autoimmune encephalomyelitis 
(EAE), a model of MS. It largely interferes with antigen presentation and activation of T cells, 
especially abrogating a Th17 response. Treatment efficiently attenuates clinical symptoms and 
myelin damage. We thereby unravel a mechanism with a dual hit on adaptive and innate 
immune functions that builds on BTK inhibition and on AG126 conversion to malononitrile 
(MN), as a novel TLR response modifier. 
 
MATERIALS AND METHODS 
 
Animals 
C57BL/6 and NMRI wildtype (wt) as well as tlr4-/-, myd88-/-, triflps2 and 2D2 mice (matching 
the C57BL/6 background) were provided by the Central Animal Facility of the University 
Medicine Göttingen (UMG) and housed under standard or pathogen-free (SPF) conditions, 
respectively, with food and water ad libitum 38. Embryonic gr+/+, gr+/- and gr-/- mice were 
obtained from the Institute for Multiple Sclerosis Research (IMSF) Göttingen 39. Animals 
were treated according to the guidelines for animal care of the University of Göttingen. 
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EAE 
Eight to 12 weeks old female C57BL/6 mice were injected subcutaneously into the flanks 
with 100 µg of myelin oligodendrocyte glycoprotein peptide (MOG35-55, PanaTecs) in a PBS 
emulsion of complete Freund’s adjuvant (Sigma, containing 1 mg/ml of Mycobacterium 
tuberculosis H37RA, Difco). After immunization and 48 h later, mice received an intravenous 
injection of 300 ng pertussis toxin in saline (List). Mice were weighed and scored daily for 
disease symptoms (see below). Mice were treated with α-cyano-[3-hydroxy-4-
nitro]cinnamonitrile (AG126, Calbiochem), malononitrile (MN) or 3-hydroxy-4-
nitrobenzaldehyde (BZ, both Sigma) diluted in DMSO (stock solutions adjusted to 50 µl for 
intraperitoneal injection) or only with vehicle over 3 to 5 days prior to, upon or following the 
onset of clinical symptoms (as indicated). At the end of the respective observation period, 
animals were anesthetized and transcardially perfused with PBS as well as 4% 
paraformaldehyde (PFA, Merck, in PBS) for histological examination or only PBS-perfused 
and sacrificed for tissue sampling, flow-cytometric and functional in vitro analyses. 
Clinical scoring 
Clinical scores were assessed daily up to 30 days as follows: 0, no clinical symptoms; 0.5, 
reduced tail tone; 1.0, limp tail, mouse cannot be rotated; 1.5, mouse can be rotated, turns 
back on its own; 2.0, mouse cannot rotate back alone; 2.5, paraparesis of one hindlimb; 3.0 
paraparesis of both hindlimbs; 3.5, paraparesis of both hind limbs and one forelimb; 4.0, 
tetraparesis (abort criterion); 5, moribund or death. Animals that had lost more than 20% of 
their maximal body weight within 48 h or that had reached a score of 4 were sacrificed by 
cervical dislocation and excluded from the experiment. 
Cell preparation and cultures 
Microglial cells were prepared from whole brains of wt, tlr4-/-, myd88-/- and triflps2 mice 
(postnatal day 0) and cultured in complete Dulbecco’s modified Eagle’s medium with 10% 
fetal calf serum (DMEM/FCS, Invitrogen/Gibco), 100 U/ml penicillin and 100 µg/ml 
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streptomycin (Biochrom) 38. Brains were freed from contaminating meninges and blood 
vessels, washed with Hank’s balanced salt solution (Biochrom) and incubated with 2.5% 
trypsin (Biochrom) for 10 min at 37°C. The reaction was stopped by adding complete 
medium, supplemented with 0.4 mg/ml DNAse (CellSystem), followed by incubation at 37°C 
for 5 min. Remaining cell clusters were mechanically separated and the suspension was 
centrifuged at 200 x g at 4°C for 10 min. Cells were resuspended in fresh complete medium 
and seeded in 75 cm2 culture flasks, which were coated with 100 µg/ml poly-L-lysine 
(Invitrogen/Gibco) for 30 min at RT and rinsed with sterile ddH2O just before being used. 
Cultures were kept in humidified atmosphere with 5% CO2 at 37°C. After one day, the 
cultures were washed 3 times (PBS, Invitrogen/Gibco) and were given fresh complete 
medium. The medium was changed every other day. After 5 days, microglial proliferation 
was stimulated by adding complete medium supplemented with 30% of L929-conditioned cell 
culture supernatant 40. After 3 to 5 days, microglia were collected from the astrocytic layer by 
shaking, washed with complete medium, counted and placed in well plates or dishes. 
Microglia preparations routinely reached a purity of >98%, as evaluated by nuclear staining 
with DAPI, immunocytochemistry for CD11b and Iba1 expression as well as by Griffonia 
simplicifolia isolectin B4 (ILB4) labeling. Routine experiments were performed in 96-well 
plates with 100 µl of medium for 18 h. 
For the preparation of gr+/-, gr-/- and gr+/+ (wt) microglia, pregnant mice were sacrificed 
by cervical dislocation. The skin was disinfected and removed on the ventral side. Uteri were 
opened, embryos separated from the placenta and transferred separately to Petri dishes filled 
with Hank’s buffered saline solution (HBSS) solution. Arms were taken for genotyping and 
brains processed individually for cell cultures to ensure genotypic homogeneity. Cells were 
finally plated in 96- and 12-well plates, or on cover slips in 12-well plates or in Petri dishes 
(34 mm) at densities of 1.5x104, 2x105 or 106 cells per well/dish, respectively. 
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Human Ramos B cells positive for IgM were cultivated to a density of 2x105 to 2x106 
cells/ml at 37°C, 5% CO2 in RPMI1640 medium with 10% FCS. Cells were collected by 
centrifugation at 4°C, pellets washed in PBS and cells concentrated to 6x106 cells/ml in 
serum-free medium. 500 µl of cell suspension were transferred to reaction tubes. 
Splenocytes were isolated and T cells were purified by MACS negative selection as 
described 41.  
Microglial experiments 
Microglia were stimulated with Pam3CSK4 ((S)-[2,3-bis(palmitoyloxy)-2(2-RS)-propyl]-N-
palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys4-OH3HCl), poly(I:C) (polyinosinic-polycytidylic acid), 
LPS (Re-LPS, Escherichia coli, serotype R515), flagellin (Salmonella typimurium strain 
14028), MALP-2 (S-[2,3-bis(palmityloxy)-(2R)-propyl–cysteinyl-GNNDESNISFKEK]), 
poly(U) (polyuridylic acid potassium salt), CpG ODN 2395 (synthetic oligodesoxynucleotide 
TCGTCGTTTTCGGCGCGCGCCG, all from Apotech) and poly(A:U) (polyadenylic acid-
polyuridylic acid, Sigma), prepared as stock solutions and kept at -20°C until use., Microglial 
cells were also treated with malononitrile (MN), 3-hydroxy-4-nitro-benzaldehyde (BZ), 
dexamethasone, DL-noradrenaline hydrochloride, phentolamine methanesulfonate, 
propranolol (Sigma), AG126, AG9, AG17, AG18, AG43, AG82, AG1288, LFM-A13, Cpd A 
(2-((4-Acetoxyphenyl)-2-chloro-N-methyl) ethylammonium chloride), 1-[(4,5-bis(4-
methoxyphenyl-2-thiazoyl)carbonyl]-4-methylpiperazine or 4-[(5-difluoromethyl-3-phenyl)-
4-isoxazolyl]benzenesulfonamide (Calbiochem /Merck) as agonists, antagonists or inhibitors 
either alone or in combination. Stock solutions were prepared in DMSO, water or PBS (as 
instructed by the manufacturer), stored at -20°C and used within recommended periods upon 
purchase. Tyrphostins were handled in the dark. Treatment of cells with inhibitors also 
involved respective pre-incubations (as outlined in the text) 
Splenocyte recall assays 
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For primary proliferative responses, spleen cells were directly isolated from AG126-treated 
mice with MOG35-55-induced EAE, cultured and challenged with MOG35-55 antigen for 72 h, 
pulsed with 1 µCi of [3H]thymidine, harvested 16 h later and analyzed for [3H] incorporation. 
Culture supernatants were collected for cytokine analyses by ELISA. In another approach, T 
cells from 2D2 mice (transgenic for a MOG-specific TCR) and T cell-free splenocytes from 
wt mice were isolated using MACS-based separation procedures (with positive and negative 
selection for CD3+ cells, Miltenyi Biotec). Preparations of the T cells (2x104) and splenocytes 
(5x105, used as APCs) were individually incubated with AG126 (100 µM, 1 h), combined and 
stimulated with MOG35-55 peptide, either in the continued presence of AG126 or without. 
Combinatory recall experiments thereby considered T cell-APC mixtures in which only one 
or both cell types had a pretreatment or where the treatment covered the entire stimulation 
period. Supernatants were finally analyzed by ELISA. 
B cell stimulation assay 
To activate BCR signaling, Ramos cells were stimulated with goat-anti-human IgM-specific 
(H+L) F(ab’)2 fragments (10 µg/ml, Jackson Immunoresearch) for 1 to 3 min at 37°C. The 
cell suspension was centrifuged (1000xg, 2 min, 4°C), medium was removed and cells were 
lysed in 100 µl of lysis buffer (50 mM Tris, ph 8.0, 150 mM NaCl, 5 mM NaF, 0.5% NP-40, 
1 mM protease inhibitor Na3VO4). Lysates were centrifuged (20,000xg, 10 min), supernatants 
were heated for 5 min at 95°C in the presence of 4x SDS-sample buffer (250 mM Tris/HCl, 
pH 6.8, 200 mM DTT, 40% glycerol, 8% SDS, 0.05% bromophenol blue) and stored at -20°C 
until immunoblot analysis. 
Cell viability 
The WST-1 cell assay was used to determine cell viability. This colorimetric method is based 
on the cleavage of the tetrazolium salt WST-1 (Roche) by the mitochondrial succinate-
tetrazolium reductase (part of the respiratory chain) of viable cells which forms a soluble dye 
(formazan). After respective stimulations, cells received fresh medium with WST-1 reagent 
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and were incubated at 37°C for 3 h. The color reaction was measured in a microplate reader 
(Model 680 or iMark, BioRad) at 450 nm with 655nm as reference. 
Flow cytometry 
Detection of cell surface and intracellular antigens as well as incorporated myelin by flow 
cytometry followed protocols described previously 42,43. To avoid nonspecific binding of 
antibodies, Fc receptors were blocked using anti-CD16/CD32 antibody (clone 2.4G2, BD 
Pharmingen). Cells were processed for flow cytometry using a panel of fluorochrome-
conjugated antibodies: CD3-FITC (clone 145-2C11), CD11b-APC (clone M1/70, both from 
eBioscience), CD45R/B220-PerCP (clone RA3-6B2), Ly6C-PE (clone AL-21), Ly6G (clone 
1A8, all from BD Biosciences), MHCI-AlexaFluor (clone KH114 and 34-1-2S) and MHCII-
AlexaFluor (clone KH116, both from BioLegend). For staining of microglia, also ILB4-FITC 
(Vector Laboratories) was used. Following treatments of microglial cultures with agonists and 
antagonists or incubation under control conditions, cells were rinsed with culture medium and 
detached from the culture dish by addition of 300 µl of 0.05% trypsin, 0.02% EDTA (w/v) 
(all Biochrom) in PBS for 3 min at 37°C, 5% CO2. The reaction was stopped by adding 600 
µl of medium. Cells were scratched off, transferred to 2 ml reaction tubes, washed with 
medium and centrifuged at 800xg for 12 min at 4°C. The supernatant was discarded and cells 
were washed in PBS or FACS buffer (2% FCS, 0.01 mM EDTA, 0.1% NaN3 in PBS, pH 8.0). 
Incubations with antibodies or ILB4 were performed for 20 and 30 min, respectively, on ice in 
the dark, followed by rinses, collection by centrifugation and resuspension. For detection of 
intracellular antigens, cells were fixed and permeabilized with Cytofix/Cytoperm (BD 
Biosciences). Subsequent incubations were performed in PBS containing 2% FCS and 0.1% 
saponin38,43. 
CNS-infiltrating cells were isolated as described 44. Preparations were incubated in 
HBSS containing collagenase and DNAse for 1 h. Cells were isolated on a Percoll gradient 
and washed twice before FACS staining. Proinflammatory T, Th1 and Th17 cell 
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differentiation was evaluated by staining with dye-labeled antibodies against surface CD3 
(Pharmingen) as well as intracellular IFNγ and IL-17 (eBioscience). 
For blood cell analyses, 3 to 4 drops of whole blood were collected into an excess 
volume (1-2 ml) of FACS buffer and mixed by shaking. Samples were centrifuged for 10 min 
at 200xg at 4°C. Supernatants discarded. Cells were resuspended by vortexing and 100 µl of 
FACS buffer containing the fluorescence-coupled antibodies was added. Samples were again 
vortexed and incubated at 4°C in the dark for 30 min. After staining, samples were vortexed 
and 1 ml of lysis buffer was directly added to the cells. Samples were again vortexed and 
incubated for 10 min at room temperature in the dark. Afterwards, the tubes were filled with 
FACS buffer, centrifuged as above and the supernatants were discarded. Washing was 
repeated once with FACS buffer. Cells were finally resuspended in 300 µl FACS buffer, 
stored at 4°C in the dark and analyzed within 48 h. 
To quantify myelin phagocytosis by microglia, myelin was purified from isolated 
brains as described (van Rossum et al. 2008; Regen et al. 2011). Purified myelin was labeled 
with FITC using an EZ-Label protein labeling kit (Pierce). FITC-labeled myelin (10 µg/ml) 
was added to the cultures for 30 or 120 min. Excess myelin was removed by rinsing twice 
with medium and once with PBS. Harvested cells were then stained with CD11b-APC, 
washed, resuspended in FACS buffer and analyzed as described above. 
Cells were acquired on FACSCalibur or LSRFortessa flow cytometers (BD 
Biosciences). Data were analyzed using FlowJo (TreeStar) and WinMDI software. 
Mitochondrial analysis 
Changes in the mitochondrial electrochemical potential gradient (∆ψ) were analyzed using a 
mitochondria staining kit (Sigma). Microglia seeded in 96-well plate were stimulated with 
TLR ligands in the presence or absence of AG12 for 18 h and JC-1 staining was performed 
according to the manufacturer’s instruction. Mitochondria with an intact membrane potential 
were revealed by the JC-1 dye as red fluorescent aggregates within the mitochondrial matrix. 
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A disrupted membrane potential was indicated when the monomeric dye was dispersed 
throughout the cell with green fluorescence. Valinomycin was employed for control treatment 
according to the manual. Besides a microscopic inspection, red and green fluorescence 
intensities were measured in a Safire UV-VIS spectrophotometer (Tecan), using 490/530 and 
525/590 nm as excitation/emission wavelengths and XFLUOR4 version 4.40 software.  
Cytokine measurements 
Recombinant mouse IFNγ, IL-17A and IL-17E were obtained in carrier-free form (R&D 
Systems). Cultures supernatants or plasma samples were analyzed by commercial ELISA for 
CCL2, CCL3, CCL5, CXCL1, IFNγ, IL-6 and IL-17 (DuoSet ELISA Development Kits, 
R&D Systems), TNFα (BioLegend) and total IL-12p40 (covering also monomeric p40, 
eBioscience). Absorbance was measured at 450 nm (with 540 nm reference) using an iMark 
microplate reader (Bio-Rad). 
Proteins and kinase activity 
Activation or activities of BTK, p38MAPK, p42/44MAPK, JNK, PLCγ2 and NFκBp65 were 
determined by ELISAs, arrays and immunoblots relying on sequence- and phosphorylation 
site-specific antibodies as well as recombinant protein references (Cell Signaling Technology, 
R&D Systems, Invitrogen). NFκBp65 activation was also analyzed by immunocytochemistry. 
The phosphorylation status of signaling molecules in microglia was analyzed by PathScan 
phospho-NFkBp65 (Ser 536), phospho-p38MAPK (Thr 180/Tyr 182), phospho-p44/42MAPK 
(ERK 1/2, Thr 202/Tyr 204) and phospho-JNK (Thr 183/Tyr 185) ELISA Kits (Cell Signaling 
Technology) according to the instructions. TLR-stimulated microglia and control cells were 
washed with ice-cold PBS and incubated with cell lysis buffer containing 1 mM of 
phenylmethylsulfonylfluoride for 5 min. Scraped cells were transferred into 1.5 ml reaction 
tubes, sonificated for 5 s at 65% intensity (Sonicator sonoplus HD 2070MS72, Bandelin) and 
centrifuged at 10,000xg for 10 min. Supernatants were taken and cleared cellular lysates were 
stored at -80°C. The whole procedure was carried out on ice. The color reaction was 
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measured in a microplate reader (Model 680, BioRad). To ensure equal protein amounts in the 
samples, GAPDH immunoblot and total protein content analyses were performed (see below). 
To analyze induced phosphorylation of MAPKs and further serine/threonine kinases a Human 
Phospho-MAPK Proteome Profiler Array was used which is also suitable for mouse study, 
based on a list confirmed analytes (R&D systems). Reactions were carried out according to 
the manufacturer’s instructions and using a Chemidoc Imager for detection (Biorad). 
BTK activity was measured by detecting the phosphorylation of tyrosine residues in a 
library of tyrosine-containing peptides with random sequences as coated on a 96-well plate of 
a pan-PTK assay (Sigma). The reaction buffer contained ATP, Mg2+ as well as Mn2+ and the 
reaction was initiated by addition of recombinant BTK (PV3363, Invitrogen) at 10 to 100 
ng/ml for various periods of time up to 60 min. The BTK was diluted to appropriate 
concentrations in enzyme dilution buffer (20 mM Tris, pH 7.5, containing 0.05% Triton R X-
100, 10% glycerol, 0.1 mg/ml BSA, 2 mM dithiothreitol and 0.5 mM Na3VO4). A monoclonal 
anti-phospho-tyrosine antibody conjugated with HRP served the conversion of a chromogenic 
substrate. Assay conditions were optimized and applied to determine inhibition by AG126 and 
LFM-A13 at 50 to 500 µM with 50 ng/ml of BTK over a 30 min reaction time, as outlined in 
the main text.  
Immunoblot detection of BTK was performed on microglial and T cell lysates. 
Microglia were taken from the standard cultures. T cell preparations reached 98% purity by 
MACS isolation. Equal amounts of protein were separated by SDS-PAGE under non-reducing 
conditions along with Precision PlusProteinWesternC Standards using a Mini-Protean 3 Cell, 
followed by a transfer to immunoblot PVDF membranes using a Semi-Dry Transfer Cell (all 
BioRad). Blots were blocked with 5% skimmed milk and subsequently developed with an 
anti-BTK antibody (raised in rabbits against the N-terminus, ABIN1031284, Antikörper 
online/ProSci Inc.) and a goat-anti-rabbit IgG-HRP (A9169, Sigma), followed by ECL 
reaction and detection (CPS-1-60, Sigma) on LumiFilm (Roche). Analyses of JNK and 
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phospho-JNK proteins were performed as described45. Detection of GAPDH involved a 
respective mouse antibody (Imgenex) and a goat-anti-mouse IgG-HRP conjugate (Sigma). 
Analyses of B cell lysates was performed with rabbit-anti-phospho-PLCγ2 (Y759) and rabbit-
anti-PLCγ2 (Cell Signaling Technology) as well as a mouse-anti-phospho-Tyr (clone 4G10, 
Upstate), following the instructions of the manufacturers) and using ECL reaction for 
visualization in a ChemiLux Imager (Intas). For reprobing, membranes were washed and 
incubated for 30 min at 50°C with stripping buffer (68.5 mM Tris, pH 6.8, 2% SDS, 100 mM 
-mercaptoethanol). 
Protein content of cellular lysates was determined using a bicinchoninic acid (BCA) 
assay (Pierce/Thermo Scientific). The color reaction was measured at 540 nm in a microplate 
reader (Model 680, BioRad). 
PCR analyses 
Polymerase chain reactions (PCR) were performed on RNA isolated from 8x106 microglial 
cells using a RNA purification kit (RNeasy Mini Kit, Qiagen). Samples of 1 µg RNA were 
treated with 1 µl of DNaseI (Roche) and 1 µl RNase Inhibitor (Promega) in 14 µl RNase free 
ddH2O for 30 min at 37°C and for another 10 min at 70°C. Thereafter, RNA was transcribed 
into cDNA using 8 µl of oligo-dT primers (Roche), 8 µl 5x buffer, 4 µl of 0.1M DTT, 4 µl 
SuperScript II Reverse Transkriptase (provided in a kit from Invitrogen) and 4 µl dNTPs 
(PeqLab) for 60 min at 37°C. The reverse transcriptase was inactivated at 95°C for 15 min. 
PCR was performed with PCR buffer, 1.5 mM MgCl2, 0.25 mM dNTPs, 1 pmol/µl of 
forward and reverse primers and 1 U Taq polymerase (Promega). The PCR program included 
steps at 94°C for 5 min, 28 or 30 cycles at 94°C for 30 s, 55.5°C for 45 s, 72°C for 45 s and 
finally 5 min at 74°C. The following forward (fw) and reverse (rv) primers (MWG) were 
used: TLR1 (fw 5’ CAA ACG CAA ACC TTA CCA GAG TG, rv 3’ GAG ATT CGG GGT 
CTT CTT TTT CC), TLR2 (fw 5’ AAA ATG TCG TTC AAG GAG, rv 3’ TTG CTG AAG 
AGG ACT GTT), TLR3 (fw 5’ ACT TGC TAT CTT GGA TGC, rv 3’ AGT TCT TCA CTT 
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CGC AAC), TLR4 (fw 5’ TCC CTG ATG ACA TTC CTT CTT, rv 3’ TGA GCC ACA TTG 
AGT TTC TTT A), TLR5 (fw 5’ CGC CTC CAT TCT TCA TTC CG, rv 3’ CCT TCA GTG 
TCC CAA ACA GTC G), TLR6 (fw 5’ CTT ACT CGG AGA CAG CAC TGA AGTC, rv 3’ 
GCA GGT GGG TGA CAT CTT TAG G), TLR7 (fw 5’ TGA CTC TCT TCT CCT CCA, rv 
3’ GCT TCC AGG TCT AAT CTG), TLR8 (fw 5’ CTG TCC AAG GTG TTA CAA TGC 
TCC, rv 3’ TTG AGA GAG GTT TCC GAA GAC G) and TLR9 (fw 5’ GGT GTG GAA 
CAT CAT TCT, rv 3’ ATA CGG TTG GAG ATC AAG). PCR products were separated in a 
1.5% agarose gel and stained with ethidium bromide. 
Spectral and spectroscopic analyses 
Characterization of chemical stability and identification of conversion products of tyrphostins 
was performed by recording UV/VIS spectra as well as applying nuclear magnetic resonance 
(NMR) spectroscopy methods to the compounds in different solvent environments. 
Tyrphostins AG18, AG82 and AG126 (50 mM in DMSO, diluted to 100 µM in medium) 
were incubated in 96-well plates with or without microglia at 37°C, 5% CO2 for different time 
periods. Afterwards, absorbance spectra (230 to 500 nm, at 2 nm intervals) were recorded at 
room temperature in a 384-well flat bottom transparent UV-permeable plates (Greiner), using 
a Safire spectrometer (Tecan, see also above). Spectra were normalized to the absorbance 
peak at 560 nm of phenol red in medium. Characteristic absorbance maxima of AG18, AG82 
and AG126 (449, 470 and 435 nm, respectively) were plotted against time. 
For NMR spectroscopy, samples of 1 or 5 mg of AG126 were prepared in 600 µl 
absolute DMSO-d6, 600 µl DMSO-d6 containing H2O and a mixture of 500 µl of DMSO-d6 
and 100 µl D2O. The solutions were transferred to 5mm NMR tubes. All NMR spectra were 
recorded on a Avance 500MHz NMR spectrometer (Bruker) at 25°C. Samples were 
monitored over a period of 21 days. 1H NMR spectra were recorded using 20 scans and 2.75 s 
acquisition. The solvent HDO peak was calibrated to 4.70 ppm. 
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Due to its low intrinsic sensitivity 13C NMR spectra were run on the 5 mg samples 
with 2048 scans in typically 1.5 h. The 13C resonances were calibrated indirectly using 
Ξ(TMS)=0.25145020 and assigned using the 2D heteronuclear single quantum correlation 
(HSQC) and heteronuclear multiple bond correlation (HMQC) experiments, optimized for 
1JCH=145 Hz and 2/3JCH =7 Hz, respectively. The 2D spectra were recorded using a spectral 
widths of 11 ppm (1H) and 110 ppm (13C), 16 or 32 scans and 1024 (1H) x 256 (13C) complex 
time domain data points in typically 4 or 8 h. 
2D Diffusion-ordered (DOSY) spectra were recorded using the ledbpgp2s sequence 
with (δ/2=2 ms) bipolar z gradients ramped from 1 to 50 G/cm, a diffusion delay (∆) of 100 
ms and longitudinal eddy current delay of 10 ms. The data matrix had a size of 8k (1H, 0.68 s 
acquisition) x 64 (diffusion dimension) and was recorded with 8 scans in typically 1 h. 
Histology and immunocytochemistry 
Mice were anesthetized and perfused through the left cardial ventricle with PBS followed by 
4% PFA, in PBS, pH 7.3. The vertebral canal, head, and specimens of liver and spleen were 
prepared and postfixed in 4% PFA at 4°C. After a rinse in PBS, spinal cord and brain were 
dissected, followed by dehydration and paraffin embedding of tissues in a Leica TP 1020 
Tissue Processor. Blocks of embedded tissue were sliced into 1 µm coronal sections with a 
Leica SM 2000 R sliding microtome and transferred to coated object slides (Superfrost Plus 
microscope slides, Thermo Scientific). Slides were dried and stored until further processing. 
Deparaffinization was performed with xylene. Subsequently, tissues sections were 
consecutively transferred to isopropanol (in (dH2O) of decreasing concentrations.  
 Haematoxylin-Eosin  (H&E) staining was performed with Mayer’s hemalaun solution 
(Merck, 5 min). Sections were washed with dH2O and differentiated with 1% HCl in 90% 
isoopropyl alcohol. Tissue was blued by rinsing slides under tap water. Sections were then 
incubated in 1% eosin solution for 5 min (1% eosin G, Merck, in 70% isopropyl alcohol, 
stirred and filtered, with 10 drops of glacial acetic acid being added before use). Afterwards, 
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slides were rinsed in dH2O, dehydrated by an alcohol series as well as xylene and mounted 
using DePex mounting medium (Serva). 
Luxol Fast Blue/Periodic Acid Schiff (LFB/PAS) staining was used to detect 
demyelinized tissue areas. Sections were incubated in LFB solution (0.1% w/v LFB in 96% 
ethanol, 0.05% acetic acid) overnight at 60°C, washed shortly in 90% ethanol, dipped in 
0.05% lithium carbonate (in dH2O, Roth), differentiated in 70% alcohol and rinsed in dH2O. 
For PAS staining, sections were incubated for 5 min in 1% periodic acid (in dH2O, Merck), 
rinsed for 5 min under tap water and shortly washed in dH2O. Sections were incubated for 20 
min in Schiff reagent (Sigma), rinsed under tap water for 5 min, kept in hemalun solution 
(Merck) for 2 min and rinsed again with dH2O. For differentiation, sections were incubated in 
1% HCl/alcohol (as above) and blued under tap water. The sections were finally dehydrated in 
an increasing alcohol series, incubated in xylene and embedded in synthetic mounting 
medium (DePeX, Serva). 
Bielschowsky silver staining was performed to determine axonal density. Sections 
were incubated in 20% silver nitrate solution (in ddH2O, Roth) for 20 min and stored in dH2O. 
Ammonium hydroxide solution (32%, Merck) was added while stirring, until precipitates 
disappeared. Further drops were added and slides were incubated in the dark for 15 min. 
Subsequently, slides were stored in ddH2O containing a few drops of ammonium hydroxide. 
Developer solution (6% formalin in dH2O, 0.4% citric acid, 0.05% nitric acid) was stirred into 
the silver nitrate/ammonium hydroxide solution. The reaction was stopped by dH2O addition, 
slides were incubated in 2% sodium thiosulfate (in dH2O) for 2 min, rinsed under water, 
dehydrated in an alcohol series and xylene and embedded in DePeX mounting medium. 
Macrophages and microglia were detected by staining tissues for the calcium-binding 
protein ionized calcium binding adaptor molecule 1 (Iba1). Slides were pretreated with citrate 
buffer (10 mM citric acid, adjusted to pH 6.0 with NaOH, both Merck) 6 x for 3 min and 
transferred to PBS. Endogenous peroxidase was blocked with 3% H2O2 in PBS for 20 min. 
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Slides were rinsed in PBS and blocked in normal serum solution (5% serum, 5% skimmed 
milk powder) for 1 h at room temperature. In general, normal serum originated from the 
animal species of the secondary antibody as applied to the respective staining. Afterwards, 
sections were incubated in the primary antibody solution of rabbit anti-Iba1 (Wako, 1:400 
diluted in 50% blocking solution in PBS) overnight at 4°C. Sections were washed 3 x 5 min 
with PBS and incubated with biotinylated donkey-anti-rabbit IgG as the secondary antibody 
(Amersham, 1:200 in 50% blocking solution in PBS) for 1 hour. Sections were again washed 
in PBS for 3 x 5 min and incubated with an avidin-peroxidase-complex solution (Sigma, 
1:1000 in 50% blocking solution, Sigma) at RT for 1 h. Sections were washed again with PBS 
and staining was developed with diaminobenzidin (DAB, Sigma), followed by rinses in dH2O. 
Sections were incubated for 3 min with Mayer’s hemalum solution (Merck) for 
counterstaining, dehydrated and embedded as for H&E staining. 
Staining of CD3, as a T cell co-receptor, followed the procedure as used for Iba1 
detection, using normal goat serum as a blocking reagent as well as rat anti-CD3 and 
biotinylated goat anti-rat-IgG as primary and secondary antibodies (Serotec, 1:100, and 
Amersham, 1:200, respectively). 
Translocation of phospho-NFkBp65 to the nucleus was analyzed for TLR-stimulated 
and control microglia cells seeded on cover slips and fixed for 15 min with PFA (4% in PBS). 
After washing with PBS, cells were incubated in permeabilization and blocking solution 
(0.1% Triton, 10% FCS in PBS), followed by incubation with rabbit-anti-phospho-NF Bp65 
(Ser536) antibody (Cell Signaling Technology, 1:500 in 10% FCS) overnight at 4°C. Cells 
were washed with PBS and incubated with the secondary antibody, an anti-rabbit-IgG-Cy3 
(1:400 in 10% FCS in PBS) for 30 min in the dark. Cells were washed again and 
counterstained with the microglia marker ILB4-FITC (1:200 in 10% FCS in PBS) for 2 h. For 
nuclear staining, washed cells were incubated with 4’-6-diamidino-2-phenylindole (DAPI, 
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1:1000 in PBS, Roche) for 10 min. Cells were washed, dipped in ddH2O and mounted with 
fluorescence mounting medium (Dako) on an slide. 
Staining of BTK in microglia was similarly carried out on microglia in vitro, following 
fixation with PFA and blocking with 2% bovine serum albumin, 5% normal goat serum in 
PBS containing 0.5% Triton X-100. The anti-BTK antibody (as shown above) and a sheep-
anti-rabbit-IgG F(ab')2-Cy3 (Sigma, 1:100) were used as primary and secondary antibodies, 
combined with ILB4-FITC and DAPI for microglial surface and nuclear staining. 
Fluorescence signals were scanned for each dye channel at 4 optical planes with 1 µm interval 
and z stacks were combined to generate overlay images. 
Staining was analyzed and images were taken with a BX51 microscope equipped with 
a DP71 camera and Cell F 2006 as well as analySIS Software (Olympus). Fluorescence 
images were taken with the Olympus microscope as also equipped with a U-RFL-T lamp 
device (Olympus) and with a Biorevo BZ-9000 microscope with integrated software 
(Keyence). 
Statistics 
Statistics were performed with the Student’s t and Mann-Whitney U tests. Differences were 
considered significant with p<0.05, individual values being indicated in the figures. 
 
RESULTS 
 
AG126 treatment is beneficial in EAE 
Since AG126 offers protection in various models of inflammatory diseases, including those of 
the CNS 27, we addressed its potential to ameliorate clinical symptoms and to mitigate tissue 
damage in mice with EAE. EAE can be induced in various animal species, by varying 
protocols and with different antigen preparations to reflect distinct clinical courses, 
neuropathological features and inflammatory conditions 46. MOG35-55-based EAE, as used 
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here, largely develops by activation of T cells, while macrophages/microglia have critical 
contributions 47,48. We found that AG126 can interfere with both. 
Upon immunization, clinical signs of paralysis developed (Fig 1A). With their onset 
around day 12, one group of animals received three daily intraperitoneal injections of AG126, 
which significantly improved their performance. Clinical scores stagnated even after 
terminating AG126 delivery. On day 22, animals were sacrificed and spinal cord tissues were 
analyzed by histology. 
 Mice with EAE and vehicle treatment revealed a massive infiltration of immune cells, 
namely CD3+ T cells, along with overt signs of white matter (myelin) damage, axonal injury 
and microglial activation (Fig 1B, Supplementary Fig 1). In contrast, mice that had received 
AG126 presented with reduced immune infiltrates, less pronounced lesions and preservation 
of white matter structures (Fig 1C). 
 We then modified the treatment schedule by administering AG126 either before or after 
clinical symptoms had manifested (Fig S2A). While preventive treatment resulted in a 
delayed disease onset and late treatment abrogated a further score increase, both application 
windows resulted only in partial white matter protection (Fig S2B). 
 Thus, even a transient AG126 treatment can reduce EAE severity when initiated with 
the appearance of clinical signs. Part of the beneficial effect may rely on the impediment of T 
cell recruitment. We had already reported on protective AG126 effects in models of CNS 
infection where it interfered with leukocyte influx 27,28. 
 
AG126 interferes with Th17 differentiation of encephalitogenic T cells 
To dissect the mechanism by which AG126 interfered with EAE, immunized mice were 
repeatedly treated with AG126 or vehicle (as in Fig 1) and sacrificed for tissue sampling. 
Splenocytes were isolated and re-challenged ex vivo with MOG35-55 antigen. Cells from 
AG126-treated mice revealed reduced proliferation, attenuated IL-2 and a virtually abolished 
 19 
IL-17 production, suggesting a major impact on Th17 cells (Fig 2A and B). In contrast, IFNγ 
was not much affected, suggesting that the Th1 subset was spared. Flow-cytometric analyses 
of CNS tissue samples confirmed a reduced infiltration by T(h17) cells following AG126 
treatment (Fig 2C), while circulating leukocyte populations were not altered (Supplementary 
Fig 2C). 
 
AG126 impedes a successful antigen presentation 
To address the main cellular target of AG126, we employed T cells from the MOG-specific T 
cell receptor (TCR)-transgenic 2D2 mouse for in vitro activation with MOG35-55 peptide in the 
presence of wt splenocytes as antigen-presenting cells (APCs) 49. Even though not fully 
suitable to study IL-17 regulation per se, this model was used to investigate AG126-mediated 
immunosuppression at cellular level. In fact, upon antigen re-challenge, AG126 impressively 
abrogated the release of IL-2, IL-6 (as a surrogate of a potentially Th17-promoting reaction) 
and IFNγ (Fig 2D). 
 In a second step, we treated purified 2D2 T cell and wt APC preparations with AG126 
separately, thereafter combined them and determined the response to a MOG35-55 challenge. 
Despite the only short pretreatment, AG126 attenuated the IL-2 release and efficiently 
suppressed the induction of IL-6 and IFNγ, especially when APCs were pretreated (Fig 2D). 
We conclude that APCs and their subsequent interaction with T cells represent a major target 
of AG126 and that this provides the immunological basis for its clinical benefit. 
  
AG126 suppresses microglia activation independently of its effect on Th17 development 
AG126 treatment also attenuated the EAE-associated microglia/macrophage activation. We 
investigated whether this effect would occur secondary to the interference with Th17 
development. 
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 IL-17 is a critical inflammatory cytokine in the pathogenesis of autoimmune diseases, 
such as MS. Its receptor IL-17R is also expressed on microglia 50. However, in vitro 
stimulation of microglia with IL-17A (the prototypic family member) and IL-17E did not 
cause much of a response in terms of inducing proinflammatory cytokines and chemokines 
which are otherwise readily triggered upon appropriate activation 51 (Supplementary Table 1). 
 In vivo, microglia are under the influence of a host of factors, especially upon tissue 
impairment. TLRs, in particular, can sense not only microbial agents, but also a variety of 
damage-released molecules. Accordingly, TLR activation drives microglial responses also in 
non-infectious situations and participates in neurodegenerative as well as autoimmune 
processes 51,52. We thus also determined IL-17 effects on TLR agonist-induced release 
activities, but observed only marginal alterations. We concluded that, in addition to its 
influence via IL-17, AG126 could directly act on microglia. 
 
AG126 has a complex influence on TLR agonist-induced microglial cytokines  
We had previously noticed that AG126 impedes microglial TLR signaling 27. Using this 
system, we sought to further decipher the mechanism of AG126 action by identifying the 
immediate target. 
TLR activation in microglia induced the production of a spectrum of cytokines and 
chemokines with important roles in immunoregulation (Supplementary Fig 3). Next, we 
determined effects of AG126 on selected TLR agonists (Fig 3A). AG126 had discrete and 
partially biphasic influences on responses to Pam3CSK4 (TLR1/2), poly(I:C) (TLR3), MALP2 
(TLR6/2) and CpG ODN (TLR9). It mostly inhibited release of TNFα, IL-6, CCL2 or CCL5, 
especially when applied at >50 µM. 
Notably, profiles differed for LPS (TLR4). AG126 caused only moderate release 
inhibition, whereas production of factors, like CXCL1, was even augmented. Consequently, 
AG126 influences were not globally suppressive and involved more than a single target. 
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 AG126 acts on TLR signaling mainly through the MyD88-dependent pathway 
While most TLRs signal through myeloid differentiation primary response gene 88 (MyD88), 
TLR3 relies on Toll-receptor-associated activator of interferon (TRIF, TICAM-1), and TLR4 
recruits both signaling adaptors 30. To narrow down on targets in these pathways, we 
determined AG126 influences on the induction of factors that critically depend on MyD88 or 
TRIF and compared their regulation in microglia with deficiencies in these signaling proteins. 
 TNFα and CXCL1 inductions depend on MyD88. They are only partially impaired by 
TRIF absence in triflps2 microglia 38. Accordingly, TLR activation failed to trigger release in 
myd88-/- microglia, but was effective in triflps2 cells (Supplementary Fig 4). AG126 presence 
then affected TNFα and CXCL1 release in wildtype (wt) and triflps2 cells, with inhibition or 
enhancement depending on the TLR (as in Fig 3A). 
IFNβ production requires TRIF. It was induced by LPS in wt but not in triflps2 cells 
(Fig 3B and C). On the other hand, AG126 did not change the respective IFNβ levels in wt or 
myd88-/- microglia. 
 The findings suggested that AG126 affects TLR signaling along the MyD88 route. To 
confirm the involvement of this pathway we determined the impact of AG126 on additional 
TLR-controlled functions, such as microglial surface expression of major histocompatibility 
class (MHC) I for antigen presentation. Its induction is selective for MHCI (no induction of 
MHCII) and depends on TRIF 38. Correspondingly, activation of TRIF via TLR3 by poly(I:C) 
and of TRIF as well as MyD88 via TLR4 by LPS resulted in MHCI upregulation (Fig 4A). 
AG126 caused only a minor effect on the TLR3→TRIF-induced MHCI level, whereas it had 
some impact (at 100 µM) on the TLR4→TRIF/MyD88-driven expression. This pattern 
suggested that AG126 could spare responses when they are solely TRIF-mediated, while 
affecting them in a cooperative signaling involving both pathways. 
 22 
 Microglia readily phagocytose myelin debris, a process which is attributed to a subset 
of cells where it is suppressed by TLR activation in a MyD88-dependent manner 38. AG126 
rescued myelin clearing activity from LPS inhibition, further pointing to the sensitivity of 
MyD88 signaling (Fig 4B and C). 
 
AG126 does not exert a global effect on MyD88-controlled signaling 
AG126 exerted only selective effects on MyD88 downstream signaling. Following TLR 
activation, nuclear translocation and phosphorylation of NFκBp65, JNK, p38 and ERK, 
respectively, were not affected in general (Supplementary Fig 5A-C), but using a 
phosphoprotein array with MAPK subtype resolution, we found AG126 to suppress TLR-
triggered phosphorylation of p38αMAPK and ERK2/p42MAPK (Supplementary Fig 5D). Since 
the overall impact on NFκB and MAPK activation was limited, the putative AG126-sensitive 
PTK would associate with the TLR/interleukin-1 receptor (IL-1R)→MyD88 signaling route, 
rather than mediating it. 
  
AG126 can directly inhibit BTK, which is expressed in microglia but not in T cells 
We had previously defined criteria for a potential target of AG126 29, which eventually led 
our search to BTK, a PTK also associating with TLRs and MyD88 53. To test the hypothesis, 
we compared effects on BTK for AG126 and LFM-A13, an established BTK inhibitor 35,53. 
Both blocked the enzymatic activity of recombinant BTK (Fig 5A). Both inhibited 
phosphorylation of phospholipase C (PLC) γ2 at Tyr759 in BCR-stimulated Ramos cells―a 
typical BTK activity (Fig 5B). 
We confirmed the expression of BTK in microglia. We detected mRNA and protein 
(Supplementary Fig 6), with a subcellular localization already reported for other cells 36. T 
cells studied in parallel were devoid of any detectable BTK levels, further adding to the 
notion that AG126 exerted effects on T(h17) cells in EAE indirectly via APC functions.  
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Although these experiments identified BTK as an AG126-sensitive PTK, AG126 and 
LFM-A13 differently influenced microglial cyto/chemokine inductions (Fig 5C). This 
suggested that BTK is a shared but not the only target. 
 
Alternative mechanisms based on the AG126 structure can be ruled out 
Besides BTK, AG126 could act on closely related PTKs. At mRNA level, we found Tec as 
the family name-giving kinase to be expressed in microglia, but not other members, like Itk, 
Rlk or Bmx. On the other hand, some tyrphostins were reported for activities exceeding PTK 
inhibition. An antioxidant action as described for AG490 54 was excluded since AG126 lacks 
a quinone-like body. 
Tyrphostins A9, AG10 and AG18 interfere with the respiratory chain coupling to 
oxidative phosphorylation and affect signaling 55,56. The uncoupling potential of AG126 was 
assessed using the fluorescent dye JC-1 for microglial staining and ratiometric analysis of the 
integrity of their mitochondrial membrane potential (∆ψ). AG126 did not cause overt 
impairment, neither alone nor in combination with TLR1/2 activation, whereas control cells 
treated with valinomycin indicated ∆ψ collapse (Supplementary Fig 7). 
 AG126 and noradrenaline are both tyrosine derivatives. They also have similar effects 
on TLR2-triggered release profiles in microglia. We thus considered agonistic activity of 
AG126 for adrenoreceptors (AR). However, while the β1/β2-adrenergic antagonist propranolol 
abolished the β2-AR-dependent suppressive effect of noradrenaline on TLR1/2-triggered 
TNFα and CXCL1 release, it had no influence on the AG126-mediated inhibition 
(Supplementary Fig 8). Similarly, phentolamine methanesulfonate (PAMS) did not rescue 
release from AG126 inhibition, ruling out any α1/α2-AR role.  
 The PTK inhibitor genistein is also a phytoestrogen, and we had shown that the plant-
derived compound A could deliver anti-inflammatory effects by serving as a non-steroidal 
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ligand of glucocorticoid receptors (GR) 57. As a modifier of TLR-triggered cyto-/chemokine 
production in microglia, it compared to dexamethasone and―notably―to AG126. 
Intriguingly, it also mimicked the peculiar increase in TLR4-induced CXCL1 levels. To 
evaluate GR involvement, we compared TNFα and CXCL1 induction in cells with GR 
deficiency (Supplementary Fig 9). While dexamethasone effects were impaired in 
heterozygous and lost in homozygous GR knockout microglia, AG126 developed influences 
on TLR1/2-induced release as it did in wt cells. Together the findings excluded such atypical 
mechanisms. 
AG126 was claimed to influence enzymes and adhesion molecules that organize for 
inflammatory mediators and cell recruitment, including IL-1R-associated kinase (IRAK), 
ICAM-1, cyclooxygenase (COX) 2 and inducible nitric oxide synthase (iNOS) 12,15,16,18,22,25,58-
64. COX2 is readily induced in TLR-stimulated microglia 43, but we ruled out that its 
suppression would play a major role, e.g. via autocrine loops (Supplementary Fig 10). 
Furthermore, we had shown that AG126 decreases NO synthesis 29. Yet interference with the 
sluggish NO production will not alter rapid cytokine release. None of these parameters could 
conclusively tell or give hints to an ultimate alternative target. 
 
NMR spectroscopy reveals fragmentation products of AG126 
Spectral HPLC analyses indicated the disappearance of AG126 from microglial cultures with 
time. To verify a suspected chemical instability we recorded changes in absorption spectra of 
AG126 and, for comparison, AG18 and AG82 in culture medium over 24 h. Normalized for 
the phenol red peak in medium (560 nm), fading of signals at 435, 449 and 470 nm revealed 
degradation, especially for AG18 and AG82. Presence of cells even facilitated the process. 
 AG126 conversion was systematically followed by NMR spectroscopy 
(Supplementary Fig 11). AG126 dissolved in absolute DMSO was stable, showing trace 
amounts of putative photodimerization products only after weeks. In contrast, AG126 
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dissolved in DMSO with residual water content (DMSOaq) slowly revealed the appearance of 
a –CHO group, which was subsequently oxidized to a carboxylic acid. The conversion rate 
increased when AG126 was prepared in a mixture of DMSOaq and D2O (1:4). Thus, AG126 
undergoes degradation under conditions applied in studies of its biological activities. 
3-Hydroxy-4-nitrobenzaldehyde (BZ) was then identified as a hydrolytic product by 
recording 1H and 13C NMR spectra of AG126 in different solvents, assigning signals to 
individual atoms in the structure. This was confirmed by analysis of a commercial BZ sample 
(Supplementary Fig 11). Stoichiometrically, AG126 decomposition to BZ ultimately also 
generates malononitrile (MN, Fig 6A). 
 
AG126 is a precursor of MN as a microglia-modulating compound  
Next we evaluated individual contributions of BZ and MN to the activity spectrum of AG126, 
comparing their influences on TLR-induced cyto-/chemokines. Exemplified for CCL2, MN 
inhibited TLR1/2- and TLR6/2-mediated inductions like AG126 did, while both spared the 
release under TLR4 stimulation (Fig 6B). Summarizing data from entire profiles, AG126 
effects correlated best with those of MN (Fig 6C). Even though direct detection of MN by 
spectroscopic methods was hampered, MN as a degradation product could mimic biological 
effects of AG126. 
 
MN has no effect on BTK and only restricted impact on MyD88 downstream signaling 
In contrast to AG126, neither MN nor BZ inhibited the enzyme activity of BTK (Fig 5A). On 
the other hand, and like AG126, MN had little influence on MyD88 downstream signaling via 
NFκB and MAPKs, except for some inhibition of p38 and ERK phosphorylation. From these 
observations and from its chemical structure, it became clear that MN would influence certain 
TLR-induced activities, but in a PTK/BTK-independent fashion. 
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AG126-related tyrphostins share microglia-modulating activity 
If MN generation underlies some of the release-affecting properties of AG126, related 
tyrphostins with a dinitrile residue should have similar effects. We tested a battery of such 
compounds (Supplementary Fig 12). Although variation in the kinetics of MN generation, the 
primary effects as PTK inhibitors or contributions of the aromatic breakdown product must be 
expected, several had AG126-like influences, including the striking upregulation of TLR4-
triggered CXCL1. 
 
Effects of AG126 and MN can superimpose  
Combination of BTK-dependent and -independent effects of AG126 and MN could explain 
the complex and partially biphasic regulation of certain cyto-/chemokine inductions (Fig 3A). 
Influences may overlay to determine the net inhibition—or even augmentation. In fact, BTK 
deficiency can cause also enhanced production of some TLR-induced cytokines, such as in B 
cells 36. We thus also considered actions of AG126/MN at two targets in EAE. 
 
Intact AG126 is required for protection in EAE 
Whereas MN mimicked AG126 effects on microglial activities, it failed to be effective in 
EAE. Treatment with MN neither reduced the clinical score nor the size of white matter 
lesions (Fig 7A and B). The number of CD3+ T cells found in CNS tissue remained 
unchanged (Fig 7C). Microglia activation was not different when compared to the control 
situation of EAE without treatment (Fig 7D). Similarly, BZ also did not affect the clinical 
course and histological outcome. 
 AG126-treated mice revealed a larger spleen, probably as a sign of reduced cell egress 
(Fig 7E). Interestingly, the individual performance of these four experimental groups in EAE 
was not adequately reflected by the levels of circulating cytokines, as exemplified by TNFα, 
IL-6 and IL-12 (Fig 7F). Some peripheral effects of MN―as indicated by reduced levels of 
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certain factors―did obviously not translate into CNS consequences. Lower serum cytokine 
levels in general did not correlate with better clinical presentation (Fig 7G). 
Taking together, neither of the two daughter products was able to replace AG126 for 
ameliorating EAE. Full efficacy in vivo depended on the parent structure. Protective potential 
of AG126 may thus primarily rely on BTK inhibition and interference with APC-T cell 
interactions. Via BTK, AG126 may influence signaling cascades in diverse cell types. As to 
TLR-triggered responses, it could have additional effects beyond those of the breakdown 
products. Essential conclusions on the mechanisms are depicted in a scheme (Fig 8). 
 
DISCUSSION 
 
AG126 protects mice with EAE and suppresses their Th17 and microglia responses 
AG126 treatment alleviated functional deteriorations, preserved white matter structures and 
reduced CNS infiltration by T cells. AG126 particularly reduced the activity of Th17 cells, 
which are responsible for substantial tissue impairment in autoimmune diseases 50. Recall 
experiments with antigen on splenocytes from AG126-treated mice revealed a dramatic 
decline of IL-17 production. Yet we also demonstrate that an IL-17 drop alone cannot account 
for attenuated microglia activation―matching data by others 50—and that AG126 rather acts 
directly on these cells. It interferes with their TLR→MyD88 signaling, a pathway with 
importance in EAE 47. Ideally, combined effects on T(h17) cells and microglia could be traced 
to a single PTK. We reveal BTK as a primary target of AG126. 
 
BTK inhibition by AG126 can affect B and T cell functions directly and indirectly 
BTK is important for B cell function and protection against infection 32, whereas therapeutic 
inhibition shows impressive effects on B cell lymphomas 33,34. On the other hand, BTK-
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dysfunctional Xid mice are less affected by inflammatory diseases 37. Proposing BTK as a 
target of AG126 in EAE agrees with these findings. 
 In B cells, IL-17 production depends on BTK 65. However, B cells do not play a major 
role in our paradigm 44, and the BTK-IL-17 link may not operate in Th17 cells. T cells do not 
express BTK 66,67. We could also not detect it in our preparations, excluding direct 
AG126→BTK actions. Our experiments on T cells from 2D2 mice indicate that AG126 
preferentially blocks T(h17) cell activation by APCs.  
 Moreover, the relative sparing of Th1 responses by AG126 in our EAE mice resembles 
the dominant Th1 profiles upon infection in human agammaglobulinemia 68. In BTK-deficient 
mice, this skewing was assigned to altered T cell priming by APCs 67. 
 
BTK inhibition by AG126 can affect microglial functions 
BTK has also implications in myeloid cells and even prognostic value in myelomas 37,69-71. 
Notably, BTK integrates in TLR signaling, although functions vary by cell types 72. 
 Reports on a rescue of mice from endotoxic shock and on LPS-induced responses 
already point to an AG126 target within TLR signaling 14,27. We nominated features for a 
candidate in microglia, i.e. constitutive expression, TLR association, a position upstream of 
stress- and mitogen-activated kinases (SAPK/MAPK, or even MEK) as well as a link to the 
control of the intracellular calcium concentration ([Ca2+]i) 27,29,73. 
 BTK fulfils these criteria. BTK activates PLCγ2 in the BCR signalosome, mobilizing 
calcium and activating protein kinase C (PKC), RasGRP, NFκB or NFAT. BTK binds TLR4, 
MyD88 and IRAK1, phosphorylates TLR3 and MyD88 adapter-like protein (MAL/TIRAP), 
the sorting adapter bridging MyD88 to TLR2 or TLR4, and supports NFκBp56 transactivation 
35,53,74,75. Association with intracellular MHCII, a novel mechanism of TLR4 signaling control 
in macrophages and dendritic cells 76, may enable BTK to distinctly affect TLR4 signaling in 
microglial subpopulations 43,77,78. 
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 BTK inhibition by AG126 can affect TLR signaling upon infection and damage 
Previous reports on AG126 in TLR-mediated responses mostly referred to infections. In 
contrast, efficacy of AG126 in EAE and other non-infectious conditions will relate to 
TLR/BTK functions as driven by endogenous agonists. TLRs sense both pathogen- as well as 
damage-associated molecular patterns (PAMPs, DAMPs) and integrate them for fighting 
infection or supporting repair, also in microglia 51. PAMPs derive from conserved structural 
motifs in microbes. DAMPs are classified as a collection of disparate, self-derived molecules 
acquiring the meaning of danger signals by non-physiological release or modification upon 
cell impairment and tissue destruction. They orchestrate a (presumably protective) sterile 
inflammation 30,31, but occasionally also fuel harmful cascades 79-81. AG126 seems to impede 
damage-driven mechanisms―with positive net outcome not only in EAE, but also in models 
of pleurisy, arthritis, pancreatitis or multiorgan failure 15,17-19. 
 
AG126 manipulates cellular functions also via a BTK-independent mechanism 
As PTK inhibitors, tyrphostins deliberately compete with protein substrates, while being 
noncompetitive for ATP. Yet some are ATP- or bisubstrate-competitive 11. Nevertheless, the 
focus on kinase inhibitor selectivity has been revisited. Actions on multiple kinome targets are 
no longer seen as disadvantageous 5. We demonstrate that AG126 is a PTK inhibitor as well 
as the precursor for an additional signaling-affecting molecule. 
 Certain tyrphostins affect signaling and transcription independently of any (known) PTK 
82. They act as antioxidants, mitochondrial uncouplers or inhibitors of G proteins and GTP-
dependent enzymes 54,55,83,84. Unconventional activities even cover stimulation of MAPKs and 
gene induction. Based on structure, AG126 is unlikely to scavenge reactive oxygen species or 
to inhibit GTPases, but it was reported to reduce the mitochondrial membrane potential and to 
increase NO-sensitive genes in certain cell models 55,82. 
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 To identify non-PTK mechanisms of AG126, we considered adrenergic and steroid-like 
effects, reasoned from its relation to tyrosine and similarities in modifying TLR-induced 
functions of microglia. However, pharmacological and knockout approaches excluded such 
actions. Neither did we obtain unequivocal evidence for uncoupling activity. 
 Our systematic search unraveled conversion of the AG126 side residue to MN. MN 
develops autarchy by phenocopying influences on microglial cyto/chemokine production in 
the absence of any BTK block. Interestingly, presence of two CN groups in tyrphostins 
correlated with kinase-independent transcriptional effects in a monocytic cell line 82, while 
instability of selected tyrphostins caused delayed increases in inhibitory activity 85. We had 
speculated on an intracellular 'depot' or interruption of critical signaling events to explain 
sustained effects of AG126―as a seemingly competitive inhibitor―despite of discontinued 
presence 27. The paradox resolves in the light of a two-compounds-two-targets mechanism 
that has also potential for other tyrphostins and beyond. 
 
AG126 and MN exert dual influences mainly on the MyD88 pathway 
Like BTK, any additional target of AG126/MN would contribute to the MyD88-conveyed 
signaling, rather than dominating it. AG126/MN impacts differ with the TLR member, and 
the pattern of effects on cytokines, MHCI as well as phagocytosis in wt, myd88-/- and triflps2 
microglia point to a predominant manipulation of MyD88 signaling, which leaves the TRIF 
route largely intact. TLRX/2 challenges obey to AG126/MN, since they exclusively rely on 
MyD88, whereas responses to TLR4 and TLR3 agonists escape AG126 control, as long as 
they are solely carried by TRIF. This notion matches previous findings 26,27,86. Yet we did not 
observe a general interception of MyD88 downstream events at NFκB, p38, ERK or JNK 
levels―a finding corroborated by other reports on AG126 15 and its relative AG556 12, in 
which actual mechanisms remained obscure. Furthermore, the weak impact of AG126 (MN) 
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on TNFα or the intriguing release enhancement for CXCL1 under TLR4 do not fit with a 
global block of MyD88 signal flow. Both factors mandatorily depend on MyD88 38. 
 
AG126/MN may affect lipid (messenger) or energy metabolism and calcium regulation 
MN derivatives were employed in anti-trypanosoma treatment 87 but nothing is known about 
biological effects of MN itself. MN may impede metabolic reactions using related molecules 
as a substrate, inhibitor or regulator. Malonyl-CoA is an intermediate in the cytosolic 
biosynthesis of long-chained fatty acids and regulates their shuttle into mitochondria for 
degradation. Malondialdehyde is an oxidative stress marker. Increased blood and tissue levels 
occur in inflammation, artherosclerosis, diabetes, neurodegenerative diseases and MS 88-90. It 
may form Schiff-base adducts with proteins and advanced lipoxidation end products. 
Proinflammatory consequences in lymphocytes involve NFκB, p38MAPK as well as PKC 
signaling and cover induction of CCL2, IL-6, ICAM-1 and COX2, among others 88. Malonate 
inhibits mitochondrial succinate dehydrogenase (complex II) activity―thereby blocking the 
citric acid cycle. 
AG126/MN had no effects on basal or TLR-enhanced WST-1 conversion, which is 
catalyzed by the mitochondrial succinate-tetrazolium reductase system, but search for MN-
exploited mechanisms may still focus on mitochondrial respiration, calcium regulation and 
connections to inflammatory signaling 91,92. We reported that AG126 abolishes a TLR(4)-
elicited elevation of [Ca2+]i in microglia, interfering with NO and cytokine synthesis 29,73. 
AG126 also lowered the basal [Ca2+]i, agreeing with an impact on a constitutive calcium 
regulator. Others confirmed [Ca2+]i as a part of TLR4 signaling 93. The situation resembles the 
role taken by BTK in BCR→PLCγ2 signaling. Yet MN would not act on BTK, and BTK-
PLCγ2 interactions in macrophage-like cells may differ from those in B cells 93. 
 
AG126/MN tandem action exemplifies a double-hit mode of signaling modulation 
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The fact that AG126―but not MN and BZ―protected mice with EAE can be interpreted in 
two ways. AG126 may escape early hydrolysis by binding to a carrier or insertion into 
membranes, acting from there on nearby targets, namely BTK. Alternatively, AG126 
conversion may lead to additional products which complement the activity spectrum. 
BTK reveals a critical participation in CNS autoimmune diseases, in addition to its 
prominent role in B cell functionality. While AG126 is shown to inhibit BTK, its follow up 
action through a breakdown product does not only serve as an example for other tyrphostins. 
It may consciously inspire the development of multi-target drugs. The MN-sensitive signaling 
element would thereby deserve attention as it determines critical outflows of TLR activation.  
Dissection of PTK-dependent and -independent principles of tyrphostin actions and 
identification of novel targets in TLR signaling potentially offer treatment alternatives in 
(neuro)inflammatory disorders and cancer.  
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FIGURES LEGENDS 
 
Figure 1: Effects of AG126 on disease outcomes in EAE. Mice immunized with MOG35-55 
for EAE induction were treated as of day 12 for three consecutive days (arrows) with AG126 
(500 µg per animal, grey square) or vehicle (controls, open square). (A) Animals were scored 
daily for clinical signs of disease up to day 22. Data are mean ± SEM, n=5 per group. Total 
scores as of day 12 differed significantly, **p<0.001. (B) Histological analyses of spinal cord 
sections (day 23) revealed white matter lesions with massive demyelination (LFB-PAS 
staining), T cell infiltration (CD3 staining) and microglia activation (Iba1 staining) in controls 
(vehicle injection), whereas AG126-treated mice had less severe outcomes. Frames indicate 
positions of images on the right. Bars represent 100 µm and 50 µm, respectively. (C) Lesion 
sizes in the experimental groups were quantified based on histology in (B), * p=0.05. 
 
Figure 2: Effects of AG126 on T cell activation and CNS recruitment in EAE. EAE was 
induced as described in Fig 1. With the onset of clinical symptoms, animals were daily treated 
with AG126 or vehicle and sacrificed on day 5 for tissue preparation. (A) Splenocyte cultures 
were prepared, stimulated with MOG35-55 peptide for 72 h and analyzed for proliferation by 
[3H]thymidine incorporation. Data are mean ± SEM, n=5 to 6 per group, measured in 
triplicates. Differences were statistically significant for all antigen concentrations (*/*/**/**, 
p values of 0.013, 0.011, 0.006 and 0.006). (B) Supernatants of splenocyte cultures challenged 
with MOG35-55 for 72 h were analyzed for IL-2, IFNγ and IL-17 concentrations to determine 
release from activated T, Th1 and Th17 cells, respectively. Data are mean ± SEM, n=6 per 
group. For IL-2, only basal release values differed significantly between groups (*p=0.04). 
Differences in IL-17 production were significant throughout (*/**, 0.004≤p≤0.002). (C) 
FACS analyses of CNS tissues (brain and spinal cord) were performed to determine infiltrated 
T cells in general (CD3+ cells) as well as subpopulations of Th1 (IFNγ+) and Th17 (IL-17+) 
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type. The two panels show representative flow cytometry plots revealing reduced T cell 
infiltration in AG126-treated mice. (D) T cells of 2D2 mice, which are transgenic for a MOG-
specific TCR, and T cell-free splenocytes from wt mice (used as APCs) were isolated, 
separately incubated with AG126 (100 µM, 1h) and combined for a stimulation with MOG35-
55 peptide for 72 h. The T cell-APC mixtures either received further AG126 to determine the 
general impact on the recall (left row) or continued in culture without AG126 to establish the 
impact of pre-treatment on either cell type (right row). Cytokine levels were then measured in 
the supernatants. Data are mean ± SEM, 6≤n≤24 per group (*/**/***, p values <0.05, <0.01 
and <0.001). 
 
Figure 3: Effects of AG126 on TLR-induced production of cytokines and chemokines. 
(A) Microglial cultures were stimulated with Pam3CSK4, LPS, MALP (all 10 ng/ml), 
poly(I:C) (50 µg/ml) or CpG ODN (5 µg/ml) in the presence of varying concentrations of 
AG126 for 18 h (including pre-incubation with AG126 for 1 h). Indicated cytokines and 
chemokines were determined in the supernatants and amounts were expressed as percentage 
of the release obtained from stimulations in AG126 absence. (B) Microglia were treated with 
TLR agonists and AG126 as in (A) and IFNβ release was measured. (C) As in (B), IFNβ 
production was determined for LPS-stimulated microglia from myd88-/-, triflps2 and matching 
wt mice in the absence or presence of AG126 (100 µM). Amounts obtained under AG126 
were expressed as percentage of the release in wt controls, levels being generally lower in 
myd88-/- than in wt cells. Data are mean ± SEM, with (A) n=24 per treatment (summarized 
from two experiments), (B) n=6 and (C) n=4. All studies were accompanied by assays on cell 
viability, based on WST-1 conversion. AG126 itself did not cause any release and did not 
impair cell vitality under any condition. 
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Figure 4: AG126 effects on TLR-controlled MHC expression and myelin phagocytosis. 
(A) Microglia were stimulated with Pam3CSK4, LPS, MALP (10 ng/ml) or poly(I:C) (50 
µg/ml) for 48 h in the absence or presence of AG126 (10 or 100 µM, including 1 h pre-
incubation), FcγRII/III-blocked, stained with FITC-ILB4 and APC-anti-MHCI antibody and 
processed for flow cytometry. Representative histograms (105 cells per sample) out of two 
experiments are shown. Parallel analyses for MHCII revealed no induction, whereas treatment 
with IFNγ (10 ng/ml as a control) resulted in a clear upregulation, which could not be blocked 
by AG126. (B, C) Microglia were treated with TLR agonists and AG126 as in (A) for 24 h, 
exposed to FITC-myelin for 30 or 120 min, labeled with APC-anti-CD11b antibody and 
processed for flow cytometry. Representative color-coded contour blots in (B) were based on 
1.5x104 cells each. Mean fluorescence intensity (MFI) was normalized for unstimulated cells 
with 120 min FITC-myelin exposure in (C). Data are mean ± SEM from 2 independent 
experiments. Significant differences are indicated for comparisons between controls and TLR-
stimulated cells (#) as well as cells with and without AG126 treatment (*). #,*p<0.05, 
**p<0.01; n.s., not significant. 
 
Figure 5: AG126 and LFM-A13 effects on BTK activity and TLR-induced cytokines. (A) 
A library of immobilized peptides containing tyrosine in random sequences was 
phosphorylated by recombinant BTK (50 ng/ml) using ATP in the absence or presence of 
AG126 or LFM-A13 at indicated concentrations. Phospho-Tyr was detected with a HRP-
conjugated antibody. Data are mean ± SEM, n=4 per group from two experiments. For a 
direct comparison, the graph also contains data on BZ and MN (see Fig 6). (B) Ramos cells 
were stimulated with anti-human IgM for 1 min in the absence or presence of AG126 or 
LFM-A13 (including 1 h preincubation). Cleared cell lysates were processed for SDS-PAGE 
and immunoblot analysis with anti-phospho-PLCγ2(Y759) antibody. Membranes were 
stripped and re-probed with an antibody against PLCγ2. Blots are taken from one of two 
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experiments. (C) Microglia were stimulated with TLR agonists as described in Fig 1. TNFα 
and CXCL1 release was determined in the absence or presence of AG126 or LFM-A13 at 
indicated concentrations (including 1 h pre-incubation). Data are mean ± SEM, n=12 from 
two experiments. 
 
Figure 6: Correlation of effects between AG126 and its degradation products. (A) 
Equation of the AG126 conversion to 3-hydroxy-4-nitro-benzaldehyde (BZ) and 
malononitrile (MN). (B) Microglia were stimulated with Pam3CSK4, LPS or MALP (10 
ng/ml) for 18 h in the absence or presence of AG126, BZ or MN (including 1 h 
preincubation). CCL2 levels were measured in the supernatants and expressed as percentage 
of the release obtained with the respective TLR agonists alone. Data are mean ± SEM, n=6 
from 2 experiments. (C) A correlation between the effects of AG126 and MN on release 
activities was based on 90 data pairs obtained from TLR1/2, TLR4 and TLR6/2 inductions of 
TNFα, IL-6, CXCL1, CCL2, CCL3 and CCL5 in the presence of various concentrations of 
the compounds (as in B). 
 
Figure 7: Effects of AG126, MN and BZ on disease outcomes in EAE. (A) EAE was 
induced as described in Figs 1 and 2. Upon disease onset, animals received AG126 or 
respective amounts of MN and BZ, or only vehicle (arrows indicate three daily injections, 
followed by two administrations every other day, see also Supplementary Fig 2). Clinical 
symptoms were scored up to day 30 when the animals got sacrificed for tissue analyses. Data 
are mean ± SEM, based on 11, 12, 11 and 10 animals with control, MN, BZ and AG126 
treatment, respectively. (B) Representative spinal cord sections from these animals reveal 
lesions in LFB-PAS staining (asterisks marking pink areas within blue white matter staining). 
The bar graph shows the quantification of the lesion sizes (mean ± SEM, 10≤n≤12 per group 
as in A). (C) Quantification of CD3+ cell infiltrates was performed in spinal cord sections of 
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the animals in (A), based on a ranking (0 for <20, + for 21 to 50, ++ for 51 to 100 and +++ for 
>100 cells/area). (D) Quantification of Iba1+ cells was performed in spinal cord sections of 
the animals in (A), based on a similar ranking as in (C). (E) Spleen weight was also 
determined in these animals. Data are mean ± SEM. (F) Blood samples were taken on day 14 
(# in A) and cytokine levels were determined in the serum. (G) Individual levels of the 
cytokines in (F) were plotted against the disease score across groups. 
 
Figure 8: Scheme of assumed mechanisms of AG126/MN actions. TLR4-agonistic PAMPs 
(‘S-mooth’ and ‘R-ough’ LPS chemotypes) or DAMPs (covering a range of intracellular, 
plasma and ECM proteins as well as carbohydrate structures) can trigger in cells, such as 
microglia, the induction of proinflammatory cytokines/chemokines for recruitment of immune 
cells. In conjunction with co-receptors, such as CD14, a TLR4/MD2 complex signals through 
pathways involving sorting (TRAM, TIRAP/MAL) and signaling adaptor proteins (TRIF, 
MyD88). MyD88 activation occurs at the cell surface-expressed TLR4, TRIF engagement 
requires CD14-assisted TLR4 endocytosis and signaling from endosomal compartments. Both 
routes cause an activation of kinase cascades (including MAPK) and transcription factors (e.g. 
IRF, AP-1 or NFκB). MyD88 organizes expression of a variety of factors, such as TNFα or 
CXCL1. TRIF characteristically drives IFNβ production. AG126 can inhibit BTK, a PTK best 
known for its role in BCR calcium signaling. In addition, BTK can interact with TLR4 and 
phosphorylate TIRAP/MAL. Modulation of microglial functions likely involves a direct 
impact of AG126 on BTK and calcium elevation, but also contributions of MN, an AG126 
breakdown product. AG126/MN effects are noticed for MyD88-dependent responses, whereas 
TRIF-inducible functions are largely spared. Note that other signaling elements were omitted 
for clarity. 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Figure 1: Histological analyses of spinal cord sections in animals with 
EAE reveal protective effects of AG126. Tissue sections as shown in Fig 1 were also 
processed for HE and Bielschowsky staining to determine total immune infiltrates and axonal 
injury. Images relate to the frames shown in Fig 1B (left, for AG126 treatment, right, for 
controls). Bars represent 50 µm. 
 
Supplementary Figure 2: AG126 partially improves the disease course in EAE also by a 
late therapeutic rather than by preventive treatment. (A) Mice MOG35-55-immunized for 
EAE induction received AG126 (500 µg per animal) or vehicle on three consecutive days 
followed by two administrations every other day (arrows). The delivery started either as of 
day 7 as a preventive treatment (pv, before the onset of the clinical symptoms) or as of day 15 
as a late therapeutic treatment (tp, after the onset of symptoms). Blood samples were taken in 
the middle of either of the 5-days treatment trains (#). Data are mean ± SEM, n=7 per group. 
(B) Animals from (A) were sacrificed on day 30 for histological analyses of spinal cord 
sections. Representative hemisections with LFB-PAS staining of white matter are shown for 
animals that had received either preventive or therapeutic AG126 treatments, next to tissues 
of their respective controls (vehicle delivery only). Asterisks mark lesion sites with pink areas 
within blue white matter staining. The bar represents 100 µm. Data from a quantification of 
the lesion sizes are shown below. (C) Blood samples taken on days 10 or 18 (preventive and 
therapeutic treatments, respectively) were analyzed for leukocyte populations. The CD11b+ 
cells would comprise monocytes, macrophages, granulocytes and natural killer cells while 
flow cytometry with antibodies against CD3 and Ly6G in combination with anti-CD11b 
identifies T cells or monocytes/granulocytes. 
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Supplementary Figure 3: TLR agonists induce microglial cytokine and chemokine 
production. (A) Primary cultures of wt microglia were treated with the specific TLR agonists 
Pam3CSK4 (TLR1/2), LPS E.coli R515 (TLR4), flagellin (TLR5), MALP2 (TLR6/2), poly(U) 
(TLR7/8) and CpG ODN (TLR9) in pathophysiological relevant concentration ranges. 
Poly(I:C) was employed for TLR3 activation (as it was found more suitable than poly(A:U)), 
but also acts on other PRRs. After 18 h of exposure, cyto- and chemokine concentrations were 
determined in the supernatants. The spectrum of factors comprised TNFα as a pluripotent 
cytokine with general pro-inflammatory actions, IL-6 as a pro- as well as anti-inflammatory 
cytokine with multiple cellular targets and induction also upon injuries and associated 
recruitment of T and B cells, IL-10 as a potent suppressor of macrophage functions, IL-12 as 
a cytokine associated with CD4 T cell differentiation into the Th1 subtype and production by 
M1-polarized macrophages (either determined as p40 total to cover all molecular versions 
containing the p40 subunit in monomeric hetero- and homodimeric form or measured as p70 
to focus on the heteromeric p35/p40 version), CCL2 (MCP1), a chemokine attracting T cells, 
monocytes, basophils and activating macrophages, CCL3 (MIP1α) as a chemokine attracting 
monocytes/macrophages, T cells (Th1>Th2), NK cells, basophils and immature dendritic 
cells, CCL5 (RANTES) as an attractor of monocytes/macrophages, T cells (T memory 
cells>Tcells, Th1>Th2), being also involved in chronic inflammation, CCL22 (MDC) causing 
chemotactic migration of dendritic cells and Th2 cells as well as CXCL1 (KC), as a potent 
attractor of neutrophils. IFNβ was included as a factor for antiviral defense and because of its 
exclusive TRIF dependence, allowing conclusions about AG126 effects on this route (see also 
Fig 3). Arrows indicate the standard concentrations applied in subsequent experiments. (B) 
Consistent with the release responses, RT-PCR analyses revealed expression of TLR1, 2, 3, 4, 
6, 8 and 9 and absence of TLR5. A product was also detected for TLR7 upon varied 
amplification conditions. Data are mean ± SEM, with n>20 culture wells from 2 experiments. 
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Supplementary Figure 4: AG126 affects MyD88-dependent cytokine and chemokine 
production in microglia. Cells deficient in TLR4 (tlr4-/-), TRIF (triflps2) or MyD88 (myd88-/-) 
were compared to matching wt cells as to the production of TNFα and CXCL1 upon 
stimulation with agonists of TLR1/2 (Pam3CSK4, 10 ng/ml), TLR4 (LPS, 10 ng/ml) and 
TLR6/2 (MALP, 10 ng/ml) in the absence (control, CTL) and presence of AG126 (100 µM) 
for 18 h. Treatment with AG126 included a pre-incubation for 1 h. Release was determined as 
in Fig S3. Data are mean ± SEM, with 16≤n≤24 per treatments of wt, tlr4-/-, triflps2 and myd88-
/- cells, respectively, as summarized from 2 to 4 preparations. 
 
Supplementary Figure 5: AG126 has little effects on TLR downstream signaling at the 
levels of NFκB and MAPK. (A) Microglia were stimulated with LPS (10 ng/ml) in the 
absence or presence of AG126 (50 µM) for 30 min. Treatment with AG126 included a 1 h 
pre-incubation. Nuclear translocation of NFκBp65 was detected as by immunocytochemistry, 
the signal (red, rabbit-anti-phospho-NFκB antibody) appearing in the nucleus (blue, DAPI) of 
the cells (green, FITC-labeled isolectin B4, ILB4, for surface carbohydrate staining). (B) 
Microglia were stimulated and treated with AG126 as in (A) for the indicated periods. 
Phosphorylated and total JNK proteins (variants of 46 and 54 kD) were detected by 
immunoblotting in cleared microglial lysates, after adjusting total protein contents. 
Representative blots of 2 experiments are shown. (C) Microglia were treated as in (A) for the 
indicated periods. Phosphorylation of NFκBp65 (Ser536), p38MAPK (Thr180/Tyr182) and 
ERK1/2 (Thr202/Tyr204) was quantified by ELISA in lysate samples of equal protein 
concentration, as also revealed by GAPDH Western blots. Data are mean ± SEM, n=3 from 2 
experiments. (D) Microglia were stimulated with Pam3CSK4 (10 ng/ml) for 15 min with and 
without AG126 (100 µM), including a preincubation as in (A). Cell lysates were then 
subjected to a phospho-MAPK array. Spot intensities were determined and normalized to the 
respective controls. This human protein array has been confirmed as applicable to certain 
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mouse factors, including ERK2. Data are mean ± SEM, n=2. Panels (A) to (C) present 
examples of experiments involving stimulations of TLR1/2, TLR3, TLR4 and TLR6/2 and 
giving similar outcomes. 
 
Supplementary Figure 6: BTK is expressed in microglia but not in T cells. (A) Microglial 
and T cells (kept in culture at 9x105 cells/dish) were lysed and equal amounts of protein from 
the cleared lysates were separated by SDS-PAGE (non-reducing conditions), transferred to 
PVDF membrane and processed for detection with an anti-BTK antibody and a secondary 
antibody-HRP conjugate. Constitutive BTK expression was determined in untreated microglia 
(kept in medium, CTL). Effects of TLR4 activation were considered by stimulation of cells 
with LPS (10 ng/ml) for 18 h prior to lysis. Molecular weight markers indicated the expected 
size. The blot is representative for 3 preparations and treatments each, respectively. (B) 
Microglia were treated with LPS or just kept in medium (as in A) and stained with anti-BTK 
as well as Cy3-labelled secondary antibodies, FITC-ILB4 and DAPI. Images reveal the 
nuclear (blue), cell surface (green) and BTK (red) stainings as well as the respective overlays. 
The insert represents non-specific labeling by the secondary antibody (red) as determined by 
omitting the anti-BTK antibody from the protocol. For clarity, these cells were only 
counterstained with DAPI, but not with FITC-ILB4. BTK expression in microglia was further 
confirmed at the mRNA level by an Illumina HiSeq2000 approach. Reporter sequences were 
identified under constitutive and various activating conditions. 
 
Supplementary Figure 7: AG126 does not affect the membrane potential of microglial 
mitochondria. Microglia were preincubated with AG126 (100 µM) or just received medium 
for 1 h, followed by treatment with TLR agonists (10 ng/ml) in the absence or presence of 
AG126 (100 µM) for 18 h. Subsequently, cells were stained with JC-1. Fluorescence 
intensities of monomers (green) and aggregates (red) were measured and expressed as their 
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ratio to evaluate mitochondrial integrity. As positive controls, cells were treated with 
valinomycin for 20 min to enforce a collapse in the membrane potential. Data are mean± 
SEM, with n>12 per group as taken from 2 experiments. 
 
Supplementary Figure 8: AG126 does not act through adrenergic receptors. Microglia 
were stimulated via TLR1/2 (Pam3CSK4, 10 ng/ml) for 18 h in the absence or presence of 
AG126 (100 µM) alone or in combination with phentolamine methanesulfonate (PAMS, 1, 10 
and 100 µM) or propranolol (PR, 0.1, 1 and 10 µM). TNFα and CXCL1 release was 
determined in the supernatants and expressed as percentage of the amounts obtained with 
TLR agonist alone (bars). Cell viability was determined by WST-1 assay (circles). Substrate 
conversion was expressed as percentage of the value obtained with unstimulated cells. Data 
are mean± SEM, with n=16 per group from 2 experiments. 
 
Supplementary Figure 9: AG126 does not act via glucocorticoid receptors. Microglia 
were prepared from gr+/-, gr-/- and gr+/+ (wt) mice at embryonic day E18.5, since complete GR 
loss is lethal at later stages. Cells were stimulated with Pam3CSK4 (10 ng/ml) in the absence 
or presence of dexamethasone (DEX, 0.1 µM) or AG126 (100 µM) for 18 h, involving also 
respective preincubations for 1 h. TNFα and CXCL1 amounts were determined in the 
supernatants and expressed as percentage of the release obtained with TLR stimulation alone. 
Cell viability was assessed by a WST-1 assay (see Fig S8). Data are mean ± SEM, with n=16 
from 2 experiments. 
 
Supplementary Figure 10: COX2 activity does not play a major role in TLR-triggered 
cytokine and chemokine release by microglia. Microglia were stimulated with (A) 
Pam3CSK4, (B) LPS or (C) MALP (all at 10 ng/ml) in the absence or presence of COX1 or 
COX2 inhibitors (FR122047, SC-791, 1-[4,5-bis(4-methoxyphenyl-2-thiazoyl)carbonyl]-4-
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methylpiperazine, 4-[(5-difluoromethyl-3-phenyl)-4-isoxazolyl]benzenesulfonamide) or their 
combination at various concentrations for 18 h. Cytokines and chemokines were determined 
in the culture supernatants and amounts were expressed as percentage of the release obtained 
from stimulations without an inhibitor. Data are mean ± SEM with n=12 to 33 from 2 to 3 
experiments. 
 
Supplementary Figure 11: NMR analyses reveal fragmentation of AG126 in aqueous 
environment. (A) AG126 dissolved in DMSO with residual amounts of water (10 mg/ml, 
DMSOaq) was analyzed by 1H NMR spectroscopy. Spectra were taken directly or after 2 and 8 
h as well as 5 and 26 days of incubation. Characteristic AG126 peaks are indicated by colored 
triangles and explained in (C). The gray triangle indicates a newly appearing peak being 
characteristic for an aldehyde. (B) AG126 was dissolved in DMSOaq or in DMSOaq mixed 
with D2O (1 volume plus 3 volumes). 1H NMR spectra were taken at the different time 
periods as indicated. The integral of the AG126 peak (white square, DMSOaq, 8.57 ppm, 
DMSO+D2O, 8.25 ppm, the peak shift being caused by the solvent) and an aldehyde peak 
(black circle, 10.0 ppm) were plotted against time of AG126 incubation. (C) 1H atoms with 
the corresponding ppm value are highlighted on the chemical structure of AG126. 13C atoms 
are correlated to a 2D HMBC (two and three-bond or heteronuclear multiple bond correlation) 
spectrum of AG126 dissolved in DMSO, with the 1H NMR spectrum shown on top and the 
13C NMR spectrum shown on the left. Traces along the characteristic H atoms (again marked 
with colored triangles) are drawn as dashed lines. Observed 13C resonances are connected to 
the corresponding C atoms in the AG126 structure by black arrows, based on correlation of 
nearby H atoms with heteronuclear single quantum coherence, one-bond correlation, and 
HMBC spectra. (D) Overlay of the 2D HMBC spectra of AG126 dissolved in DMSO (green) 
and in DMSO+D2O (red). The peaks in the two samples are slightly shifted due to different 
solvent compositions. Addition of D2O led to the appearance of new signals corresponding to 
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an aldehyde. The carbonyl 13C resonance is at 192.7 ppm, but appears folded at 82.7 ppm. The 
gray dotted line illustrates the cutout shown in (C). The box in the 1H spectrum indicates H2 
protons as analyzed by diffusion-ordered spectroscopy, which was performed to detect further 
(breakdown) structures according to their substance size. (E) Overlay of 2D HMBC spectra of 
AG126 dissolved in DMSO+D2O and BZ as an identified breakdown product. While the pure 
sample of BZ revealed the aldehyde signals, the C atoms of the nitrile part of AG126 were not 
detected, as expected. The stoichiometric balance suggested malononitrile (MN) as a second 
product. However, MN could not be identified directly in 1H NMR spectra, presumably 
because the CH2 resonance was hidden under the residual water signal or because of a 
transformation into a CD2 group by exchange with the solvent. 
 
Supplementary Figure 12: Correlation of effects between AG126 and related tyrphostin 
members. The chemical structure illustrates individual substitutions at the ring positions as 
they differ from AG126. Microglia were stimulated with the TLR agonists in the absence or 
presence of tyrphostins as in Fig 6. TNFα and CXCL1 amounts were determined and 
expressed as percent of control levels. Data are mean ± SEM, with n=8 from 2 experiments. 
AG17 was excluded from the release data presentation since it probably impaired the cell 
vitality, as indicated by reduced WST-1 conversion. 
 
Supplementary Table 1: Microglial cytokine and chemokine release in response to 
stimulation with IL-17 and TLR agonists. Microglial cultures were stimulated with IL-17A 
or IL-17E either alone or in combination with Pam3CSK4 or LPS for 18 h at the indicated 
concentrations. Cytokines and chemokines were determined in the supernatants. Data are 
mean ± SEM with n=8 to 16 per group as taken from 2 experiments. Statistical analyses were 
performed by the Mann-Whitney U test. *p<0.05, **p<0.01 and ***p<0.001 as to significant 
differences compared to medium control; *p(●)<0.05 for significant difference between the 
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combined stimulation with a TLR agonist (Pam3CSK4 or LPS) and an IL-17 form compared 
to the respective TLR stimulation alone; n.d., not detectable. 17A or IL-17E alone induced 
some significant but only minute amounts of TNFα, CCL2, CCL3, CCL5 and CXCL1. While 
all combined stimulations were significantly different from the medium control (with 
p<0.001, not further indicated), the IL-17 proteins had only small effects in addition. 
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SUPPLEMENTARY TABLE 
 
Supplementary Table 1: Microglial cytokine and chemokine release in response to stimulation with 
IL-17 and TLR agonists. Microglial cultures were stimulated with IL-17A or IL-17E either alone or in 
combination with Pam3CSK4 or LPS for 18 h at the indicated concentrations. Cytokines and 
chemokines were determined in the supernatants. Data are mean ± SEM with n=8 to 16 per group as 
taken from 2 experiments. Statistical analyses were performed by the Mann-Whitney U test. 
*p<0.05, **p<0.01 and ***p<0.001 as to significant differences compared to medium control; 
*p(●)<0.05 for significant difference between the combined stimulation with a TLR agonist 
(Pam3CSK4 or LPS) and an IL-17 form compared to the respective TLR stimulation alone; n.d., not 
detectable. 17A or IL-17E alone induced some significant but only minute amounts of TNFα, CCL2, 
CCL3, CCL5 and CXCL1. While all combined stimulations were significantly different from the medium 
control (with p<0.001, not further indicated), the IL-17 proteins had only small effects in addition.  
 
Treatment Concentration [pg/ml] 
Factor [g/ml] TNFα IL-6 CCL2 CCL3 CCL5 CXCL1 
medium  2.3±0.9 3.7±1.5 7.0±1.7 63.3±15.7 n.d. n.d. 
IL-17A 10-9 7.0±1.9 
*p=0.032 
5.6±2.6 
 
9.8±2.8 
 
92.6±13.7 
 
n.d. 
 
n.d. 
 
10-8 13.1±3.7 
*p=0.015 
5.7±4.4 
 
13.6±4.3 
 
132.2±13.5 
**p=0.008 
75.2±23.6 
***p<0.001 
n.d. 
 
10-7 15.3±5.1 
*p=0.030 
11.2±4.8 
 
29.5±4.0 
***p<0.001 
149.9±11.9 
**p=0.002 
28.8±14.1 
*p=0.011 
11.7±6.0 
**p=0.003 
IL-17E 10-9 10.6±2.8 
*p=0.011 
8.4±3.0 
 
15.6±3.5 
 
114.3±12.2 
*p=0.019 
5.4±5.1 
 
n.d. 
 
10-8 15.8±3.8 
**p=0.001 
5.7±2.6 
 
14.8±3.1 
 
134.3±9.6 
**p=0.002 
103.3±29.8 
***p<0.001 
n.d. 
 
10-7 25.5±4.9 
***p<0.001 
8.4±3.1 
 
24.6±4.3 
**p=0.005 
142.2±11.6 
**p=0.003 
15.7±9.5 
**p=0.003 
8.2±3.4 
**p=0.003 
Pam3CSK4 10-8 2648.8±68.7 
***p<0.001 
2663.9±46.8 
***p<0.001 
653.7±67.2 
***p<0.001 
13621.8±1201.0 
***p<0.001 
4191.3±255.5 
***p<0.001 
5228.2±401.7 
***p<0.001 
+ IL-17A 10-9 2530.7±142.0 
 
2418.5±165.8 693.3±88.8 16421.6±2020.6 3986.9±280.3 4751.4±441.8 
10-8 2858.5±150.3 
 
3010.6±185.0 
*p=0.035(●) 
762.1±91.9 
 
14105.7±2025.9 
 
4611.9±274.5 
 
5816.1±780.3 
 
10-7 2579.1±74.5 
 
2579.3±104.2 812.8±116.6 14970.5±1177.7 4173.8±282.4 4927.5±527.4 
+ IL-17E 10-9 2547.5±83.9 
 
2445.9±148.8 634.7±105.9 13134.8±813.7 4010.5±418.0 4792.5±631.9 
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10-8 2401.8±92.6 
*p=0.032(●) 
2397.8±116.3 
*p=0.047(●) 
577.3±68.8 21271.7±9115.6 3965.5±232.5 4690.1±382.6 
10-7 2312.4±205.4 2452.0±84.7 
*p=0.037(●) 
609.6±69.6 11553.8±1076.2 3951.8±255.2 4691.7±520.3 
LPS 10-8 3230.2±217.5 
***p<0.001 
6445.0±759.2 
***p<0.001 
2476.2±333.9 
***p<0.001 
13298.4±1295.1 
***p<0.001 
28803.9±335.1 
***p<0.001 
1500.1±95.6 
***p<0.001 
+ IL-17A 10-9 3754.2±225.8 6764.7±907.6 3359.1±480.0 
**p=0.002 
15732.0±2500.4 28978.0±473.4 1688.0±151.8 
10-8 3243.3±187.9 
 
6472.7±1016.1 3743.9±310.6 
*p=0.027(●) 
15445.3±2073.9 28432.1±448.6 1465.4±160.6 
10-7 3557.2±238.3 
 
6519.8±918.6 3371.7±301.6 14307.5±2594.4 29932.1±541.4 1803.0±109.3 
+ IL-17E 10-9 3217.3±161.6 
 
5829.5±980.5 3041.7±462.1 12211.5±1554.5 28459.4±373.4 1327.2±120.4 
10-8 3929.5±592.9 
 
6676.6±925.1 2872.6±306.9 12606.0±1351.7 28238.6±401.4 1720.3±54.1 
10-7 3160.7±126.6 
 
5274.8±667.8 3197.2±393.9 16905.3±5107.9 27972.8±477.9 1629.7±80.5 
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